Your browser is no longer supported. Please, upgrade your browser.
Larimar Therapeutics, Inc.
Index- P/E- EPS (ttm)-3.07 Insider Own1.10% Shs Outstand16.00M Perf Week-1.58%
Market Cap200.62M Forward P/E- EPS next Y-2.61 Insider Trans386.23% Shs Float6.23M Perf Month-12.96%
Income-49.20M PEG- EPS next Q-0.64 Inst Own86.40% Short Float7.59% Perf Quarter38.11%
Sales- P/S- EPS this Y75.50% Inst Trans8.34% Short Ratio3.60 Perf Half Y-27.65%
Book/sh4.22 P/B2.95 EPS next Y8.70% ROA-50.10% Target Price- Perf Year-16.01%
Cash/sh4.37 P/C2.84 EPS next 5Y- ROE-58.10% 52W Range7.00 - 25.87 Perf YTD-41.94%
Dividend- P/FCF- EPS past 5Y36.00% ROI- 52W High-51.95% Beta0.91
Dividend %- Quick Ratio9.60 Sales past 5Y- Gross Margin- 52W Low77.57% ATR1.00
Employees28 Current Ratio9.60 Sales Q/Q- Oper. Margin- RSI (14)47.38 Volatility7.88% 8.00%
OptionableYes Debt/Eq0.00 EPS Q/Q42.00% Profit Margin- Rel Volume0.53 Prev Close11.97
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume131.38K Price12.43
Recom1.70 SMA20-7.20% SMA501.88% SMA200-14.20% Volume69,639 Change3.84%
Feb-10-21Initiated JMP Securities Mkt Outperform
Feb-01-21Initiated William Blair Outperform $29
Sep-16-21 08:00AM  
Sep-02-21 04:01PM  
Aug-22-21 10:12AM  
Aug-19-21 07:00AM  
Aug-12-21 07:00AM  
Aug-09-21 08:48AM  
Jul-23-21 12:00PM  
Jul-08-21 04:01PM  
Jun-11-21 07:00AM  
Jun-05-21 07:55PM  
Jun-02-21 10:56PM  
Jun-01-21 04:55AM  
May-29-21 10:59PM  
May-25-21 05:41PM  
May-21-21 09:18AM  
May-20-21 04:31PM  
May-11-21 07:00AM  
May-10-21 04:05PM  
Mar-04-21 07:00AM  
Mar-01-21 03:54AM  
Feb-18-21 04:01PM  
Dec-16-20 07:23PM  
Dec-15-20 08:00AM  
Dec-08-20 07:30AM  
Nov-13-20 08:00AM  
Nov-10-20 08:00AM  
Oct-14-20 10:18PM  
Oct-13-20 08:00AM  
Sep-21-20 09:58AM  
Sep-10-20 08:00AM  
Sep-01-20 12:47PM  
Aug-11-20 07:00AM  
Aug-04-20 08:00AM  
Jul-28-20 08:00AM  
Jul-20-20 04:15PM  
May-29-20 04:05PM  
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases. The company's lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare and progressive genetic disease. Larimar Therapeutics, Inc. is headquartered in Bala Cynwyd, Pennsylvania.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Flynn James EDirectorJun 30Buy8.75685,7105,999,9621,943,423Jul 02 05:07 PM